2022年度我国脑胶质瘤领域研究进展

陈雯琳; 王月坤; 刘千舒; 叶立果; 郑智尧; 张鑫; 龚乐; 曹雅宁; 宋怡萱; 郭晓鹏; 王裕; 马文斌

doi:10.12290/xhyxzz.2023-0321

2022年度我国脑胶质瘤领域研究进展

Annual Research Progress of Glioma in China in 2022

摘要

摘要: 脑胶质瘤是成人中枢神经系统发病率最高的原发恶性肿瘤, 尽管目前已有包括手术切除、放疗及化疗等多种治疗手段, 患者生存期仍较短, 严重威胁患者的生命健康。近年来, 随着对胶质瘤基础和临床特性研究的不断深入, 脑胶质瘤领域也得到进一步发展。本文就2022年度我国脑胶质瘤领域中有关胶质瘤的分类、发生机制、免疫微环境、影像学研究、临床研究(手术治疗、放疗、替莫唑胺化疗、靶向治疗及免疫治疗)、新型药物递送系统及大数据应用技术等方面研究进展进行综述, 以期为脑胶质瘤的临床诊疗提供参考。

Abstract: Glioma, the most prevalent primary malignant tumor of the adult central nervous system, is highly malignant. Despite the current clinical treatment options including surgical resection, radiotherapy and chemotherapy, the survival period of patients is still relatively short, which poses a serious threat to patients' lives and health. In recent years, the research on glioma has made great progress, and the study on the mechanism of glioma development and the characteristics of the immune microenvironment has also deepened. At the same time, researches on molecular pathological typing of glioma, comprehensive clinical diagnostic and therapeutic programs, novel drug delivery systems and big data clinical translation are also steadily underway. This article reviews the research progress in the field of glioma in China in 2022, with the hope of providing reference for clinical diagnosis and treatment.

HTML全文

参考文献(71)

施引文献

资源附件(0)